Johan Karlsson Wallman
41 – 50 of 60
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis : Results from the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis : results from the SWEFOT trial population
(
- Contribution to journal › Article
-
Mark
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis : pooled analysis of two phase 3 studies
(
- Contribution to journal › Article
- 2018
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article
- 2017
-
Mark
A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
(
- Contribution to journal › Article
-
Mark
Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy : A population-based regional cohort study from southern Sweden
(
- Contribution to journal › Article
- 2016
-
Mark
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
(
- Contribution to journal › Article
-
Mark
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis : Results of a Randomized Swedish Trial
(
- Contribution to journal › Article